Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001847367-25-000028
Filing Date
2025-05-14
Accepted
2025-05-14 16:32:03
Documents
84
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alms-20250331x10q.htm   iXBRL 10-Q 2234225
2 EX-31.1 alms-20250331xex31d1.htm EX-31.1 15384
3 EX-31.2 alms-20250331xex31d2.htm EX-31.2 14888
4 EX-32.1 alms-20250331xex32d1.htm EX-32.1 9675
5 EX-32.2 alms-20250331xex32d2.htm EX-32.2 9098
  Complete submission text file 0001847367-25-000028.txt   9255311

Data Files

Seq Description Document Type Size
6 EX-101.SCH alms-20250331.xsd EX-101.SCH 71417
7 EX-101.CAL alms-20250331_cal.xml EX-101.CAL 59992
8 EX-101.DEF alms-20250331_def.xml EX-101.DEF 285086
9 EX-101.LAB alms-20250331_lab.xml EX-101.LAB 609472
10 EX-101.PRE alms-20250331_pre.xml EX-101.PRE 464681
87 EXTRACTED XBRL INSTANCE DOCUMENT alms-20250331x10q_htm.xml XML 1408555
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42143 | Film No.: 25946322
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)